Adavosertib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAdavosertib
Drug Alias NameL001739996-008UAZD-1775MK-1775AZ-1775MK-1775 hemihydrate
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitors
TargetsSerine/threonine-protein kinase WEE1
Therapy Area/IndicationsBrain metastasesEsophageal adenocarcinomaCardia Cancer +[78] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe Netherlands Cancer InstituteFrance National Cancer Institute +[8] 
Inactive CompaniesMerck Sharp & Dohme CorpUniversity Of BirminghamUniversity Of Washington +[4] 
Active IndicationsBrain metastasesEsophageal adenocarcinomaCardia Cancer +[56] 
Inactive IndicationsOral Squamous Cell Carcinomauterine serous carcinomaMyelodysplastic Syndromes +[22] 

Other Information

ATC CodeN/A
Related LinksN/A